209187-02-0
Chemical Structure
YM-60828 methanesulfonate
- CAS. Nr.: 209187-02-0
- Formula:C28H35N5O8S2
- Molecular Weight:633.74
IUPAC Name: 2-(N-((7-carbamimidoylnaphthalen-2-yl)methyl)-N-(4-((1-(1-iminoethyl)piperidin-4-yl)oxy)phenyl)sulfamoyl)acetic acid compound with methanesulfonic acid (1:1)
InChIKey: YRIFGKTUAWTSFP-UHFFFAOYSA-N
SMILES: O=S(N(CC1=CC=C2C=CC(C(N)=N)=CC2=C1)C(C=C3)=CC=C3OC4CCN(CC4)C(C)=N)(CC(O)=O)=O.O=S(O)(C)=O
Biological Activity: YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders[1][2][3][4][5].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
YM-60828 methanesulfonate | YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sato K, et al. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol. 1998 Apr 24;347(2-3):231-6. [Content Brief]
- [2]. Hirayama F, et al. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor. Bioorg Med Chem. 2002;10(5):1509-1523. [Content Brief]
- [3]. Kawasaki T, et al. Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis. Thromb Haemost. 1998;79(4):859-864. [Content Brief]
- [4]. Kawasaki T, et al. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost. 1998;79(2):410-416. [Content Brief]
- [5]. Taniuchi Y, et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost. 1998;79(3):543-548. [Content Brief]
